BioState

Biostate AI is a precision health company headquartered in Houston, TX, that connects samples, data, and decisions to redefine how diseases are detected, predicted, and managed. With a mission to help 90% of humanity live to 90 years old, Biostate AI integrates next-generation wetlab technology, multi-omics data generation, and biomedical artificial intelligence to deliver earlier, smarter clinical insights. The platform serves researchers, clinicians, and health systems seeking scalable, cost-efficient solutions for genomic and transcriptomic analysis, disease prediction, and drug response modeling.

Biostate AI operates through a global collaboration network spanning the United States, China, India, and Saudi Arabia, with more than 20 collaborating institutions. Its ecosystem includes wholly owned subsidiaries and joint ventures, each focused on regional precision health implementation and innovation.

Core Technology Platform

• BIRT (Barcode-Integrated Reverse Transcription) + PERD (Probes for Excess RNA Depletion): Patented technologies enabling efficient, multiplexed RNA processing with cleaner data. This approach requires 10× less sample and delivers RNAseq at 10× lower cost compared to traditional methods, unlocking earlier, data-driven insights for precision medicine.
• MARE (Massively Accurate Rare Exome): A pending-patent DNAseq technology delivering greater than 98% exome coverage and detecting 5,000+ inherited diseases years before symptoms appear. Designed to address the problem that over 90% of genetic diseases are diagnosed 2–7 years late, MARE enables proactive care and prevention of avoidable disability and death.
• Wetlab Innovation: Biostate's wetlab platform enables large-scale, high-fidelity RNA and DNA sequencing for real biological data generation at unprecedented scale and cost efficiency — achieving approximately 85% lower cost — forming the foundation for AI-driven disease prediction and drug response models.
• Biomedical AI: AI-driven models turn biological signals into actionable clinical insights, empowering clinicians with predictions for earlier and smarter care. Biostate's AI visualization tools support clinical decision-making across disease areas.

K-Dense: Autonomous AI Scientist

• K-Dense is a Biostate AI spinout based in Palo Alto, CA, focused on autonomous scientific research — from hypothesis generation through to publication.
• K-Dense has achieved state-of-the-art benchmark performance, with results reported as more than 50% better than GPT-5 on the BixBench (Open Answer) benchmark.
• The platform produces publication-ready scientific text in Nature-Cell style, enabling researchers to accelerate the research and publication process.
• K-Dense is co-founded and led by Timothy Kassis, Ph.D., formerly an Instructor at MIT and Head of AI and Data Metaworks.

Global Subsidiary and Joint Venture Network

• Biostate AI (Houston, TX): Global headquarters and primary hub for wetlab innovation, AI development, and sample access.
• K-Dense (Palo Alto, CA): U.S.-based spinout focused on autonomous AI-driven scientific research.
• Biosheng (Shanghai, China): Subsidiary dedicated to advancing precision medicine and intelligent diagnostics through local innovation and implementation in China.
• Baisheng (Wuhan, China): A joint venture between Biostate AI and Kindstar Global, a publicly listed company, combining world-class omics innovation with large-scale clinical deployment.
• Bayosthiti AI (Bengaluru, India): Subsidiary advancing AI-driven precision and lifetime health management in India.
• Biostate AI MENA (Riyadh, Saudi Arabia): Subsidiary focused on population-scale multi-omics and AI-driven precision health implementation across the Middle East and North Africa region.

Leadership Team

• David Zhang, Ph.D. — Co-founder and CEO: Presidential award-winning bioengineering professor with 60+ top publications and 40+ patents. Previously Associate Professor of Bioengineering at Rice University (2013–2021) and Co-founder & CEO of NuProbe Global. Raised $100M+ in venture capital from Sequoia and AstraZeneca, reaching $21M in annual revenue in 2022.
• Jeremy Sobotta — CFO: Former CFO of Padagis LLC and Perimeter Medical Imaging AI; Senior Financial Leader at Stryker; deployed $4B+ in M&A capital with extensive experience in biotech and medtech scaling.
• Kutapa Muthanna — CEO, Bayosthiti AI (India): Former Director at KPMG and Lead Software Engineer at Fidelity.
• Mohammad Alkweihewi — CEO, Biostate AI MENA (Saudi Arabia): Former Managing Director at Eurofins Clinical KSA, Director of Private Sector Partnerships at the Ministry of Health KSA, and Director of Research at Princess Noura University.
• Zoe Zheng — CEO, Biosheng (China): Former Partner at Alpha Ventures and Principal at Matrix Partners China.
• Alden Yao — CEO, Baisheng (Wuhan JV): Deputy General Manager at Kindstar Global Gene Technology Co., Ltd. since 2012.
• Timothy Kassis, Ph.D. — Co-Founder & Head of AI, K-Dense: Former Instructor at MIT and Head of AI and Data Metaworks.

Investors and Advisors

• Biostate AI is backed by institutional and individual investors including notable figures such as Dario Amodei (Founder & CEO, Anthropic), Emily Leproust (Founder & CEO, Twist Bioscience), Mike Schnall-Levin (CTO, 10x Genomics), Joris Poort (Founder & CEO, Rescale), and Arpan Sheth (Senior Partner, Bain & Company), among others.
• The company is supported by a world-class scientific advisory board including George Church (Harvard Medical School, NGS Technology), Robert Sanchez (HCA Florida Heart Institute), Abhijit Patel (Yale Medical School, Lung Cancer), Ghayas Issa (MD Anderson, Leukemia), Peter Dedon (MIT, RNA Epigenetics), Sarah Elsea (Baylor College of Medicine, Inherited Diseases), Stanley Hazen (Cleveland Clinic, Cardiovascular Disease), Keith Flaherty (Massachusetts General Hospital, Melanoma), and others spanning autoimmune diseases, blood disorders, COPD, chronic pain, and pediatric diseases.

Biostate AI brings together patented wetlab technologies, a global network of subsidiaries and collaborating institutions, and cutting-edge biomedical AI to make precision health accessible and actionable at population scale — connecting samples, data, and decisions across the full continuum of care.